Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02413736Phase 3Active Not Recruiting

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Role: lead

NCT02216149Phase 2Terminated

Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Role: lead

NCT00515931Phase 1Completed

Radiation Therapy as Palliative Treatment of GIST

Role: lead

All 3 trials loaded